Status at 3 months in asymptomatic patients at baseline
| Total (n=2052) | Germany (n=795) | France (n=542) | UK (n=715) | P value | |
| Patients available/lost to FU, n (%) | 2039/13 | 786/9 | 542/0 | 711/4 | |
| Asymptomatic patients, n (%) | 416 (20.4) | 81 (10.3) | 152 (28.0) | 183 (25.7) | <0.001 |
| AVR planned, n (%) | 142 (34.1) | 59 (72.8) | 56 (36.8) | 27 (14.8) | <0.001 |
| AVR indicated* | 40 (28.2) | 25 (42.4) | 12 (21.4) | 3 (11.1) | 0.004 |
| AVR performed, n (%) | 32 (80.0) | 20 (80.0) | 11 (91.7) | 1 (33.3) | 0.134 |
| TAVI, n (%) | 23 (71.9) | 17 (85.0) | 5 (45.5) | 1 (100.0) | 0.054 |
| SAVR, n (%) | 9 (28.1) | 3 (15.0) | 6 (54.5) | 0 (0) | |
| AVR not performed, n (%) | 8 (20.0) | 5 (20.0) | 1 (8.3) | 2 (66.7) | 0.134 |
| AVR not indicated | 102 (71.8) | 34 (57.6) | 44 (78.6) | 24 (88.9) | 0.004 |
| AVR performed, n (%) | 69 (67.6) | 30 (88.2) | 34 (77.3) | 5 (20.8) | <0.001 |
| AVR not performed, n (%) | 33 (32.4) | 4 (11.8) | 10 (22.7) | 19 (79.2) | |
| AVR not planned, n (%) | 274 (65.9) | 22 (27.2) | 96 (63.2) | 156 (85.2) | <0.001 |
*Based on LVEF <50%, Vmax >5.5 m/sec, PAP sys >60 mm Hg.
AVR, aortic valve replacement; FU, follow-up; LVEF, left ventricular ejection fraction; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.